98%
921
2 minutes
20
Background: Population-based studies have shown that cardiometabolic status is associated with the amount of white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI). However, little is known of cardiometabolic risk factors in the subcortical small vessel type of dementia (SSVD), in which WMHs are one of the most prominent manifestations.
Objective: To determine whether the profile of cardiometabolic risk factors differed between SSVD, Alzheimer's disease (AD), mixed dementia (combined AD and SSVD), and healthy controls.
Methods: This was a mono-center, cross-sectional study of SSVD (n = 40), AD (n = 113), mixed dementia (n = 62), and healthy controls (n = 94). In the statistical analyses, we adjusted for covariates using ANCOVA and binary logistic regression.
Results: The prevalence of hypertension was increased in SSVD and mixed dementia (p < 0.001 and p < 0.05 versus controls, respectively). Diabetes was more prevalent in SSVD patients, and body mass index was lower in AD and mixed dementia, compared to the controls (all p < 0.05). Serum total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) were reduced in the SSVD group (both p < 0.05 versus control). These differences remained after adjustment for covariates. In the SSVD group, Trail Making Test A score correlated positively with systolic blood pressure, mean arterial pressure, and pulse pressure.
Conclusion: All dementia groups had an altered cardiometabolic risk profile compared to the controls. The SSVD patients showed increased prevalence of hypertension and diabetes, and in line with previous population-based data, TC and LDL-C in serum were reduced.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3233/JAD-191077 | DOI Listing |
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
Sleep
September 2025
Center for Sleep Medicine, Hospices Civils de Lyon, Lyon 1 University, Lyon, F-69000, France.
Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program.
View Article and Find Full Text PDFChronobiol Int
September 2025
Consultant, Wayzek Science, St Paul, Minnesota, USA.
Understanding how sleep affects the risk of incident chronic conditions in midlife may reinforce the importance of a healthy sleep pattern for healthy aging and cardiometabolic health. The objective of the study was to examine associations of sleep duration and quality with incident obesity, diabetes and metabolic syndrome in mid-aged adults. Participants without obesity ( = 381), diabetes ( = 509), or metabolic syndrome ( = 487) from the Biomarker Projects in Midlife in the United States study were examined separately for baseline sleep duration and quality and their associations with incident obesity, diabetes, or metabolic syndrome after an average follow-up of 12 years.
View Article and Find Full Text PDFJ Comp Eff Res
September 2025
British Heart Foundation, University of Glasgow, Glasgow, UK.
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory approval. However, employing composite endpoints introduces complexities into health technology assessments (HTAs), particularly in economic modeling, due to the varying clinical significance and cost implications of the components. In this paper, we explore best modeling practice for HTAs that are based on clinical trials that employ composite endpoints.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
September 2025
School of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.